Latest clinical guidelines on melanoma management consider immune checkpoint blockade (anti-PD-1 alone or in combination with anti-CTLA4) as a first-line treatment option for unresectable stage III and IV melanoma patients [20,21]. The gene discussed is CTLA4; the disease is melanoma.